UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals
In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.
In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”
Quest Diagnostics closed on Wednesday at $57.30.
Latest Ratings for DGX
|Jul 2014||Canaccord Genuity||Maintains||Hold|
|May 2014||Bank of America||Upgrades||Underperform||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.